NYSE:LLY - Eli Lilly and Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$81.83 -0.24 (-0.29 %)
(As of 05/21/2018 04:00 PM ET)
Previous Close$82.16
Today's Range$81.68 - $82.53
52-Week Range$73.69 - $89.09
Volume189,622 shs
Average Volume4.65 million shs
Market Capitalization$89.08 billion
P/E Ratio19.12
Dividend Yield2.76%
Beta0.26

About Eli Lilly and (NYSE:LLY)

Eli Lilly and logoEli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions. The company also provides neuroscience products for the treatment of depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorder; obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains, as well as immunology products to treat Alzheimer's disease. In addition, it offers oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia; and migraine. Further, the company provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry use; and chewable tablets that kill fleas and prevent heartworm diseases. Additionally, it offers vaccines to prevent bordetella, Lyme disease, rabies, and parvovirus. The company has collaboration agreements with Daiichi Sankyo Co., Ltd.; Incyte Corporation; Pfizer Inc.; AstraZeneca; and Nektar Therapeutics, as well as has strategic collaboration with Sigilon Therapeutics. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Receive LLY News and Ratings via Email

Sign-up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:LLY
CUSIP53245710
Phone317-276-2000

Debt

Debt-to-Equity Ratio0.64
Current Ratio1.41
Quick Ratio1.01

Price-To-Earnings

Trailing P/E Ratio19.12
Forward P/E Ratio15.86
P/E Growth1.42

Sales & Book Value

Annual Sales$22.87 billion
Price / Sales3.88
Cash Flow$5.5216 per share
Price / Cash14.82
Book Value$10.60 per share
Price / Book7.72

Profitability

EPS (Most Recent Fiscal Year)$4.28
Net Income$-204,100,000.00
Net Margins4.82%
Return on Equity35.37%
Return on Assets11.30%

Miscellaneous

Employees40,655
Outstanding Shares1,085,430,000

Eli Lilly and (NYSE:LLY) Frequently Asked Questions

What is Eli Lilly and's stock symbol?

Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

How often does Eli Lilly and pay dividends? What is the dividend yield for Eli Lilly and?

Eli Lilly and announced a quarterly dividend on Monday, May 7th. Stockholders of record on Thursday, May 17th will be paid a dividend of $0.5625 per share on Friday, June 8th. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.75%. The ex-dividend date is Wednesday, May 16th. View Eli Lilly and's Dividend History.

How were Eli Lilly and's earnings last quarter?

Eli Lilly and Company (NYSE:LLY) posted its quarterly earnings results on Tuesday, April, 24th. The company reported $1.34 EPS for the quarter, beating the consensus estimate of $1.13 by $0.21. The firm had revenue of $5.70 billion for the quarter, compared to analysts' expectations of $5.51 billion. Eli Lilly and had a net margin of 4.82% and a return on equity of 35.37%. The company's revenue was up 9.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.98 earnings per share. View Eli Lilly and's Earnings History.

When is Eli Lilly and's next earnings date?

Eli Lilly and is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Eli Lilly and.

What guidance has Eli Lilly and issued on next quarter's earnings?

Eli Lilly and issued an update on its FY18 earnings guidance on Tuesday, April, 24th. The company provided EPS guidance of $5.10-5.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.87. The company issued revenue guidance of $23.7-24.2 billion, compared to the consensus revenue estimate of $23.43 billion.

What price target have analysts set for LLY?

19 equities research analysts have issued 1 year price objectives for Eli Lilly and's shares. Their forecasts range from $78.00 to $115.00. On average, they expect Eli Lilly and's stock price to reach $93.5556 in the next year. View Analyst Ratings for Eli Lilly and.

What are Wall Street analysts saying about Eli Lilly and stock?

Here are some recent quotes from research analysts about Eli Lilly and stock:
  • 1. According to Zacks Investment Research, "Lilly’s new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance and Lartruvo have been driving revenues and the trend is expected to continue in 2018. Lilly expects to launch 20 new products between 2014 and 2023, including at least two new indications/line extensions on an average every year. The decision to sell or spin-off the Animal Health segment, which underperformed in 2017, is a prudent decision in our view. However, competitive pressure on Lilly’s drugs is expected to rise this year. Meanwhile, challenges remain for the company in the form of loss of patent exclusivity for products like Cialis and the impact of generic competition for Strattera, Effient and Axiron. U.S. pricing access pressure will also remain a headwind in 2018. Nontheless, estimates have gone up ahead of the Q1 earnings release. Lilly has a positive record of earnings surprises in recent quarters." (4/11/2018)
  • 2. Jefferies Group LLC analysts commented, "Date and time of first dissemination: July 17, 2017, 08:17 ET Date and time of production: July 17, 2017, 08:17 ET Target Price / Valuation Methodology: Mallinckrodt plc – MNK Our discounted cash flow (DCF) analysis leads us to a price target of $87/share for MNK shares. Our DCF considers our estimates through 2027, slowing growth through 2033 and a 10% terminal decline thereafter. In addition, we expect Mallinckrodt’s margin structure to remain somewhat consistent with our 2027 estimates. We estimate a weighted average cost of capital (WACC) of 11.4% which is in line with other companies in Mallinckrodt’s peer set due to the company’s manageable leverage and consistent cash generation potential." (7/13/2017)

Who are some of Eli Lilly and's key competitors?

Who are Eli Lilly and's key executives?

Eli Lilly and's management team includes the folowing people:
  • Mr. David A. Ricks, Chairman, CEO & Pres (Age 50)
  • Dr. Jan M. Lundberg, Exec. VP of Science & Technology (Age 64)
  • Mr. Michael J. Harrington, Sr. VP & Gen. Counsel (Age 55)
  • Mr. Enrique A. Conterno, Sr. VP, Pres of Lilly Diabetes & Pres of Lilly USA (Age 51)
  • Mr. Joshua L. Smiley, Sr. VP & CFO (Age 48)

Has Eli Lilly and been receiving favorable news coverage?

News coverage about LLY stock has been trending positive this week, Accern Sentiment reports. The research group rates the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Eli Lilly and earned a daily sentiment score of 0.28 on Accern's scale. They also assigned news coverage about the company an impact score of 46.56 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Who are Eli Lilly and's major shareholders?

Eli Lilly and's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.06%), PRIMECAP MANAGEMENT COMPANY (5.00%), Franklin Resources Inc. (3.00%), Northern Trust Corp (1.04%), Massachusetts Financial Services Co. MA (0.73%) and Legal & General Group Plc (0.43%). Company insiders that own Eli Lilly and stock include Alfonso G Zulueta, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, Michael J Harrington, R David Hoover and Susan Mahony. View Institutional Ownership Trends for Eli Lilly and.

Which major investors are selling Eli Lilly and stock?

LLY stock was sold by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP, Neuberger Berman Group LLC, Amundi Pioneer Asset Management Inc., Sei Investments Co., Northern Trust Corp, Massachusetts Financial Services Co. MA, Swiss National Bank and Eaton Vance Management. Company insiders that have sold Eli Lilly and company stock in the last year include Alfonso G Zulueta, Donald A Zakrowski, Jeffrey N Simmons, Joshua L Smiley, Lilly Endowment Inc, Melissa S Barnes, Michael J Harrington and Susan Mahony. View Insider Buying and Selling for Eli Lilly and.

Which major investors are buying Eli Lilly and stock?

LLY stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Schroder Investment Management Group, BlackRock Inc., LSV Asset Management, Alps Advisors Inc., Mackay Shields LLC, Point72 Asset Management L.P. and W. E. Donoghue & Co. LLC. Company insiders that have bought Eli Lilly and stock in the last two years include Jackson P Tai and R David Hoover. View Insider Buying and Selling for Eli Lilly and.

How do I buy shares of Eli Lilly and?

Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eli Lilly and's stock price today?

One share of LLY stock can currently be purchased for approximately $81.83.

How big of a company is Eli Lilly and?

Eli Lilly and has a market capitalization of $89.08 billion and generates $22.87 billion in revenue each year. The company earns $-204,100,000.00 in net income (profit) each year or $4.28 on an earnings per share basis. Eli Lilly and employs 40,655 workers across the globe.

How can I contact Eli Lilly and?

Eli Lilly and's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company can be reached via phone at 317-276-2000 or via email at [email protected]


MarketBeat Community Rating for Eli Lilly and (LLY)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  770 (Vote Outperform)
Underperform Votes:  611 (Vote Underperform)
Total Votes:  1,381
MarketBeat's community ratings are surveys of what our community members think about Eli Lilly and and other stocks. Vote "Outperform" if you believe LLY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LLY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Eli Lilly and (NYSE:LLY) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
19 Wall Street analysts have issued ratings and price targets for Eli Lilly and in the last 12 months. Their average twelve-month price target is $93.5556, suggesting that the stock has a possible upside of 14.33%. The high price target for LLY is $115.00 and the low price target for LLY is $78.00. There are currently 8 hold ratings and 11 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldBuy
Consensus Rating Score: 2.582.582.472.50
Ratings Breakdown: 0 Sell Rating(s)
8 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
7 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $93.5556$93.50$93.1176$90.8235
Price Target Upside: 14.33% upside16.99% upside14.71% upside8.76% upside

Eli Lilly and (NYSE:LLY) Consensus Price Target History

Price Target History for Eli Lilly and (NYSE:LLY)

Eli Lilly and (NYSE:LLY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2018Credit Suisse GroupSet Price TargetHold$82.00LowView Rating Details
5/10/2018BMO Capital MarketsReiterated RatingHold$78.00LowView Rating Details
4/18/2018HC WainwrightReiterated RatingBuyLowView Rating Details
4/13/2018Jefferies GroupSet Price TargetBuy$90.00LowView Rating Details
2/26/2018JPMorgan ChaseSet Price TargetBuy$105.00MediumView Rating Details
2/1/2018Bank of AmericaLower Price TargetNeutral ➝ Neutral$88.00 ➝ $86.00LowView Rating Details
1/16/2018Goldman SachsDowngradeBuy ➝ Neutral$86.98 ➝ $95.00HighView Rating Details
1/5/2018ArgusUpgradeHold ➝ Buy$85.52 ➝ $115.00MediumView Rating Details
11/21/2017Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$86.00 ➝ $90.00N/AView Rating Details
10/26/2017Berenberg BankReiterated RatingBuy$98.00N/AView Rating Details
10/23/2017Leerink SwannBoost Price TargetMarket Perform$92.00 ➝ $93.00N/AView Rating Details
10/13/2017Piper Jaffray CompaniesReiterated RatingBuy$105.00N/AView Rating Details
10/13/2017BarclaysBoost Price TargetOverweight$90.00 ➝ $98.00N/AView Rating Details
10/4/2017CowenReiterated RatingBuy$95.00LowView Rating Details
7/26/2017UBSDowngradeHold$85.00MediumView Rating Details
7/26/2017OppenheimerDowngradeOutperform ➝ Market Perform$90.00 ➝ $90.00LowView Rating Details
7/17/2017Deutsche BankReiterated RatingBuy$90.00 ➝ $91.00LowView Rating Details
7/4/2017CitigroupReiterated RatingBuy$100.00LowView Rating Details
5/21/2017Sanford C. BernsteinReiterated RatingOutperform$88.00MediumView Rating Details
11/25/2016Atlantic SecuritiesDowngradeOverweight ➝ NeutralN/AView Rating Details
10/27/2016Societe GeneraleReiterated RatingHold$78.00N/AView Rating Details
6/15/2016SunTrust BanksReiterated RatingBuyN/AView Rating Details
(Data available from 5/21/2016 forward)

Earnings

Eli Lilly and (NYSE:LLY) Earnings History and Estimates Chart

Earnings by Quarter for Eli Lilly and (NYSE:LLY)

Eli Lilly and (NYSE:LLY) Earnings Estimates

2018 EPS Consensus Estimate: $4.95
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$1.08$1.14$1.11
Q2 20182$1.25$1.31$1.28
Q3 20182$1.17$1.28$1.23
Q4 20182$1.30$1.37$1.34

Eli Lilly and (NYSE LLY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/24/2018$1.29N/AView Earnings Details
4/24/2018Q1 2018$1.13$1.34$5.5139 billion$5.70 billionViewN/AView Earnings Details
1/31/2018Q4 2017$1.08$1.14$5.9349 billion$6.1610 billionViewN/AView Earnings Details
10/24/2017Q3 2017$1.03$1.05$5.5181 billion$5.6580 billionViewN/AView Earnings Details
7/25/2017Q2 2017$1.05$1.11$5.5985 billion$5.8243 billionViewN/AView Earnings Details
4/25/2017Q1 17$0.96$0.98$5.2156 billion$5.2280 billionViewN/AView Earnings Details
1/31/2017Q416$0.98$0.95$5.54 billion$5.76 billionViewN/AView Earnings Details
10/25/2016Q316$0.96$0.88$4.23 billion$5.19 billionViewListenView Earnings Details
7/26/2016Q216$0.86$0.86$5.14 billion$5.40 billionViewListenView Earnings Details
4/26/2016Q116$0.85$0.83$4.82 billion$4.87 billionViewListenView Earnings Details
1/28/2016Q415$0.78$0.78$5.33 billion$5.38 billionViewListenView Earnings Details
10/22/2015Q315$0.76$0.89$4.99 billion$4.96 billionViewListenView Earnings Details
7/23/2015Q215$0.74$0.90$4.89 billion$4.98 billionViewListenView Earnings Details
4/23/2015Q115$0.76$0.87$4.62 billion$4.64 billionViewN/AView Earnings Details
1/30/2015Q414$0.74$0.75$5.21 billion$5.12 billionViewN/AView Earnings Details
10/23/2014Q314$0.66$0.66$4.83 billion$4.88 billionViewListenView Earnings Details
7/24/2014Q214$0.66$0.68$4.88 billion$4.94 billionViewN/AView Earnings Details
4/24/2014Q114$0.70$0.70$4.78 billion$4.68 billionViewN/AView Earnings Details
1/30/2014Q413$0.72$0.74$5.46 billion$5.81 billionViewListenView Earnings Details
10/23/2013Q313$1.04$1.11$5.76 billion$5.77 billionViewN/AView Earnings Details
7/24/2013Q2 2013$1.01$1.16$5.82 billion$5.93 billionViewN/AView Earnings Details
4/24/2013Q1 2013$1.05$1.14$5.66 billion$5.60 billionViewN/AView Earnings Details
1/29/2013Q4 2012$0.82$0.85$5.78 billion$5.96 billionViewN/AView Earnings Details
10/24/2012$0.82$0.79ViewN/AView Earnings Details
7/25/2012$0.76$0.83ViewN/AView Earnings Details
4/25/2012$0.80$0.92ViewN/AView Earnings Details
1/31/2012$0.80$0.87ViewN/AView Earnings Details
10/20/2011$1.12$1.13ViewN/AView Earnings Details
7/21/2011$1.18$1.18ViewN/AView Earnings Details
4/18/2011$1.16$1.24ViewN/AView Earnings Details
1/27/2011$1.10$1.11ViewN/AView Earnings Details
10/21/2010Q3 2010$1.15$1.21ViewN/AView Earnings Details
7/22/2010Q2 2010$1.11$1.24ViewN/AView Earnings Details
4/19/2010Q1 2010$1.11$1.18ViewN/AView Earnings Details
1/28/2010Q4 2009$0.92$0.91ViewN/AView Earnings Details
10/21/2009Q3 2009$1.02$1.20ViewN/AView Earnings Details
7/22/2009Q2 2009$1.02$1.12ViewN/AView Earnings Details
4/20/2009Q1 2009$0.99$1.20ViewN/AView Earnings Details
1/29/2009Q4 2008$1.05$1.07ViewN/AView Earnings Details
10/23/2008Q3 2008$1.01$1.04ViewN/AView Earnings Details
7/24/2008Q2 2008$0.99$0.99ViewN/AView Earnings Details
4/21/2008Q1 2008$0.95$0.92ViewN/AView Earnings Details
1/29/2008Q4 2007$0.89$0.90ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Eli Lilly and (NYSE:LLY) Dividend Information

Eli Lilly and pays an annual dividend of $2.25 per share, with a dividend yield of 2.75%. LLY's next quarterly dividend payment will be made on Friday, June 8. The company has grown its dividend for the last 3 consecutive years and is increasing its dividend by an average of 2.00% each year. Eli Lilly and pays out 52.57% of its earnings out as a dividend.
Next Dividend:6/8/2018
Annual Dividend:$2.25
Dividend Yield:2.75%
Dividend Growth:2.00% (3 Year Average)
Payout Ratio(s):52.57% (Trailing 12 Months of Earnings)
43.60% (Based on This Year's Estimates)
41.36% (Based on Next Year's Estimates)
40.75% (Based on Cash Flow)
Track Record:3 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Eli Lilly and (NYSE:LLY)

Eli Lilly and (NYSE:LLY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/7/2018quarterly$0.56252.86%5/16/20185/17/20186/8/2018
12/11/2017quarterly$0.56252.59%2/14/20182/15/20183/9/2018
10/16/2017quarterly$0.522.42%11/14/201711/15/201712/8/2017
6/19/2017quarterly$0.522.51%8/11/20178/15/20179/8/2017
5/1/2017quarterly$0.522.55%5/11/20175/15/20176/9/2017
12/13/2016quarterly$0.523.03%2/13/20172/15/20173/10/2017
10/17/2016quarterly$0.512.59%11/10/201611/15/201612/9/2016
6/20/2016quarterly$0.512.81%8/11/20168/15/20169/9/2016
5/2/2016quarterly$0.512.68%5/11/20165/13/20166/10/2016
12/8/2015quarterly$0.512.43%2/10/20162/12/20163/10/2016
10/19/2015quarterly$0.502.57%11/10/201511/13/201512/10/2015
6/15/2015quarterly$0.502.42%8/12/20158/14/20159/10/2015
5/4/2015quarterly$0.502.78%5/14/20155/18/20156/10/2015
12/15/2014quarterly$0.502.89%2/11/20152/13/20153/10/2015
10/20/2014quarterly$0.493.03%11/12/201411/14/201412/10/2014
6/16/2014quarterly$0.493.31%8/13/20148/15/20149/10/2014
5/5/2014quarterly$0.493.35%5/13/20145/15/20146/10/2014
12/16/2013quarterly$0.493.98%2/12/20142/14/20143/10/2014
10/21/2013quarterly$0.493.91%11/13/201311/15/201312/10/2013
6/18/2013quarterly$0.493.82%8/13/20138/15/20139/10/2013
5/6/2013quarterly$0.493.62%5/14/20135/16/20136/10/2013
12/17/2012quarterly$0.493.96%2/13/20132/15/20133/8/2013
(Data available from 1/1/2013 forward)

Insider Trades

Eli Lilly and (NYSE LLY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.11%
Institutional Ownership Percentage: 76.10%
Insider Trading History for Eli Lilly and (NYSE:LLY)
Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Eli Lilly and (NYSE LLY) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/11/2018Lilly Endowment IncMajor ShareholderSell140,000$81.97$11,475,800.00122,755,804View SEC Filing  
5/3/2018Jeffrey N SimmonsSVPSell9,027$78.50$708,619.50View SEC Filing  
4/25/2018Lilly Endowment IncMajor ShareholderSell180,000$80.85$14,553,000.00122,896,904View SEC Filing  
4/16/2018Susan MahonySVPSell22,544$80.09$1,805,548.9645,652View SEC Filing  
4/13/2018Susan MahonySVPSell5,165$80.14$413,923.1045,652View SEC Filing  
3/16/2018Joshua L SmileyCFOSell3,000$79.20$237,600.0020,029View SEC Filing  
3/1/2018Donald A ZakrowskiInsiderSell860$76.50$65,790.00View SEC Filing  
2/21/2018Donald A ZakrowskiInsiderSell876$77.55$67,933.804,130View SEC Filing  
2/5/2018Donald A ZakrowskiInsiderSell900$81.09$72,981.004,130View SEC Filing  
2/5/2018Jeffrey N SimmonsSVPSell9,625$81.12$780,780.00152,120View SEC Filing  
12/13/2017Lilly Endowment IncMajor ShareholderSell200,000$88.20$17,640,000.00123,084,104View SEC Filing  
12/11/2017Jeffrey N SimmonsSVPSell12,500$86.46$1,080,750.00124,522View SEC Filing  
12/4/2017Susan MahonySVPSell36,585$86.18$3,152,895.3054,885View SEC Filing  
11/10/2017Alfonso G ZuluetaSVPSell2,003$83.67$167,591.0143,580View SEC Filing  
10/4/2017Lilly Endowment IncMajor ShareholderSell205,000$86.81$17,796,050.00View SEC Filing  
9/29/2017Lilly Endowment IncMajor ShareholderSell195,000$85.14$16,602,300.00123,513,247View SEC Filing  
9/15/2017Lilly Endowment IncMajor ShareholderSell190,000$82.53$15,680,700.00123,682,287View SEC Filing  
8/31/2017Lilly Endowment IncMajor ShareholderSell180,000$81.06$14,590,800.00123,865,804View SEC Filing  
7/31/2017Lilly Endowment IncMajor ShareholderSell220,000$83.09$18,279,800.00124,049,283View SEC Filing  
6/22/2017Lilly Endowment IncMajor ShareholderSell210,000$84.43$17,730,300.00124,265,804View SEC Filing  
6/20/2017Lilly Endowment IncMajor ShareholderSell215,000$83.05$17,855,750.00124,475,804View SEC Filing  
6/12/2017Melissa S BarnesInsiderSell1,900$80.78$153,482.0014,041View SEC Filing  
6/9/2017Michael J HarringtonVPSell22,833$79.97$1,825,955.0162,056View SEC Filing  
5/4/2017Enrique A ConternoSVPSell25,000$82.76$2,069,000.00114,217View SEC Filing  
3/30/2017Lilly Endowment IncMajor ShareholderSell210,000$84.67$17,780,700.00124,690,804View SEC Filing  
2/17/2017Lilly Endowment IncMajor ShareholderSell230,000$80.27$18,462,100.00125,125,804View SEC Filing  
2/6/2017Alfonso G ZuluetaSVPSell15,000$77.66$1,164,900.0045,583View SEC Filing  
2/3/2017Derica W RiceEVPSell11,162$77.14$861,036.6858,443View SEC Filing  
2/2/2017Donald A ZakrowskiInsiderSell2,000$77.52$155,040.00886View SEC Filing  
2/1/2017Lilly Endowment IncMajor ShareholderSell220,000$77.35$17,017,000.00125,359,047View SEC Filing  
12/16/2016Lilly Endowment IncMajor ShareholderSell200,000$72.59$14,518,000.00125,649,408View SEC Filing  
12/16/2016Melissa S BarnesInsiderSell2,093$82.23$172,107.398,169View SEC Filing  
12/16/2016R David HooverDirectorBuy500$71.85$35,925.0033,504View SEC Filing  
12/16/2016Susan MahonySVPSell20,242$72.65$1,470,581.3067,802View SEC Filing  
10/5/2016Maria A CroweInsiderSell2,248$81.37$182,919.7694,319View SEC Filing  
8/15/2016Jackson P TaiDirectorBuy5,773$80.43$464,322.3942,306View SEC Filing  
8/12/2016Jackson P TaiDirectorBuy2,560$80.42$205,875.2042,110View SEC Filing  
7/29/2016Lilly Endowment IncMajor ShareholderSell205,000$82.94$17,002,700.00125,775,804View SEC Filing  
7/28/2016Donald A ZakrowskiInsiderSell1,213$83.16$100,873.081,300View SEC Filing  
7/28/2016Lilly Endowment IncMajor ShareholderSell240,000$82.87$19,888,800.00126,020,570View SEC Filing  
7/12/2016Lilly Endowment IncMajor ShareholderSell210,000$79.54$16,703,400.00126,220,804View SEC Filing  
7/7/2016Lilly Endowment IncMajor ShareholderSell225,000$79.14$17,806,500.00126,442,509View SEC Filing  
6/30/2016Lilly Endowment IncMajor ShareholderSell215,000$78.46$16,868,900.00126,808,704View SEC Filing  
6/29/2016Lilly Endowment IncMajor ShareholderSell220,000$77.86$17,129,200.00126,963,785View SEC Filing  
6/10/2016Melissa S BarnesSVPSell992$73.77$73,179.8410,710View SEC Filing  
5/31/2016Lilly Endowment IncMajor ShareholderSell200,000$75.12$15,024,000.00127,090,804View SEC Filing  
5/12/2016Jackson P TaiDirectorBuy1,080$75.75$81,810.0040,600View SEC Filing  
5/12/2016Lilly Endowment IncMajor ShareholderSell190,000$75.86$14,413,400.00127,295,910View SEC Filing  
5/2/2016Donald A ZakrowskiCAOSell1,600$75.86$121,376.003,113View SEC Filing  
4/29/2016Lilly Endowment IncMajor ShareholderSell180,000$75.44$13,579,200.00127,481,005View SEC Filing  
4/27/2016Alfonso G ZuluetaSVPSell12,000$76.27$915,240.0045,101View SEC Filing  
4/8/2016Lilly Endowment IncMajor ShareholderSell200,000$74.29$14,858,000.00127,660,804View SEC Filing  
2/5/2016Stephen F FrySVPSell15,230$78.87$1,201,190.1059,690View SEC Filing  
2/3/2016David A. RicksSVPSell5,733$77.66$445,224.7879,403View SEC Filing  
2/3/2016Derica W. RiceCFOSell10,483$77.78$815,367.7436,931View SEC Filing  
2/1/2016Jackson P TaiDirectorBuy3,170$78.62$249,225.4039,487View SEC Filing  
1/29/2016Alfonso G ZuluetaSVPSell5,000$78.75$393,750.0057,101View SEC Filing  
12/21/2015Lilly Endowment IncMajor ShareholderSell205,000$86.00$17,630,000.00127,860,804View SEC Filing  
12/15/2015Lilly Endowment IncMajor ShareholderSell215,000$85.60$18,404,000.00128,065,804View SEC Filing  
12/9/2015Enrique A ConternoVPSell25,000$83.88$2,097,000.0088,131View SEC Filing  
12/2/2015Lilly Endowment Incmajor shareholderSell210,000$85.09$17,868,900.00128,280,804View SEC Filing  
11/20/2015Lilly Endowment Incmajor shareholderSell205,000$84.54$17,330,700.00128,490,804View SEC Filing  
10/29/2015Lilly Endowment Incmajor shareholderSell200,000$82.28$16,456,000.00128,695,804View SEC Filing  
10/9/2015Lilly Endowment Incmajor shareholderSell215,000$85.86$18,459,900.00128,895,804View SEC Filing  
10/5/2015Lilly Endowment Incmajor shareholderSell260,000$86.46$22,479,600.00129,110,804View SEC Filing  
9/18/2015Lilly Endowment Incmajor shareholderSell250,000$89.04$22,260,000.00129,370,804View SEC Filing  
6/10/2015Lilly Endowment IncMajor ShareholderSell210,000$82.39$17,301,900.00View SEC Filing  
6/4/2015Lilly Endowment IncMajor ShareholderSell200,000$77.90$15,580,000.00View SEC Filing  
5/29/2015Jeffrey N SimmonsSVPSell20,000$78.08$1,561,600.00View SEC Filing  
5/20/2015Lilly Endowment IncMajor ShareholderSell190,000$73.43$13,951,700.00View SEC Filing  
5/15/2015Lilly Endowment IncMajor ShareholderSell200,000$72.83$14,566,000.00View SEC Filing  
5/8/2015Lilly Endowment IncMajor ShareholderSell195,000$73.28$14,289,600.00View SEC Filing  
5/1/2015Lilly Endowment IncMajor ShareholderSell200,000$73.09$14,618,000.00View SEC Filing  
3/30/2015Lilly Endowment IncMajor ShareholderSell180,000$73.94$13,309,200.00View SEC Filing  
3/23/2015Lilly Endowment IncMajor ShareholderSell190,000$76.97$14,624,300.00View SEC Filing  
3/9/2015Stephen F FrySVPSell4,000$69.27$277,080.00View SEC Filing  
2/4/2015David A RicksSVPSell3,147$69.99$220,258.53View SEC Filing  
2/4/2015Derica W RiceCFOSell5,316$70.00$372,120.00View SEC Filing  
2/4/2015Jan M LundbergEVPSell11,085$70.08$776,836.80View SEC Filing  
2/3/2015Jan M LundbergEVPSell121,711$70.78$8,614,704.58View SEC Filing  
2/2/2015David A RicksSVPSell4,769$71.51$341,031.19View SEC Filing  
2/2/2015Derica W RiceCFOSell10,068$71.84$723,285.12View SEC Filing  
12/4/2014Lilly Endowment IncMajor ShareholderSell190,000$71.92$13,664,800.00View SEC Filing  
12/2/2014Lilly Endowment IncMajor ShareholderSell180,000$70.14$12,625,200.00View SEC Filing  
11/13/2014Lilly Endowment IncMajor ShareholderSell200,000$67.73$13,546,000.00View SEC Filing  
11/5/2014Lilly Endowment IncMajor ShareholderSell180,000$67.00$12,060,000.00View SEC Filing  
11/4/2014Fionnuala M WalshSVPSell15,000$67.00$1,005,000.00View SEC Filing  
11/3/2014Enrique A ConternoVPSell5,000$66.03$330,150.00View SEC Filing  
10/31/2014Fionnuala M WalshSVPSell7,376$66.58$491,094.08View SEC Filing  
10/31/2014Lilly Endowment IncMajor ShareholderSell190,000$66.40$12,616,000.00View SEC Filing  
10/30/2014Lilly Endowment IncMajor ShareholderSell175,000$66.58$11,651,500.00View SEC Filing  
10/24/2014Maria A CroweInsiderSell2,750$65.77$180,867.50View SEC Filing  
10/6/2014Lilly Endowment IncMajor ShareholderSell210,000$65.63$13,782,300.00View SEC Filing  
10/1/2014Enrique A ConternoVPSell5,000$64.86$324,300.00View SEC Filing  
9/30/2014Lilly Endowment IncMajor ShareholderSell200,000$65.07$13,014,000.00View SEC Filing  
9/10/2014Lilly Endowment IncMajor ShareholderSell210,000$64.77$13,601,700.00View SEC Filing  
9/3/2014Lilly Endowment IncMajor ShareholderSell200,000$63.99$12,798,000.00View SEC Filing  
9/2/2014Enrique A ConternoVPSell5,000$63.60$318,000.00View SEC Filing  
7/29/2014Lilly Endowment IncMajor ShareholderSell250,000$63.03$15,757,500.00View SEC Filing  
7/28/2014Susan MahonySVPSell2,065$63.30$130,714.50View SEC Filing  
7/25/2014Enrique A ConternoVPSell10,000$63.79$637,900.00View SEC Filing  
7/25/2014Susan MahonySVPSell30,000$63.90$1,917,000.00View SEC Filing  
7/1/2014Lilly Endowment IncMajor ShareholderSell235,000$62.30$14,640,500.00View SEC Filing  
6/25/2014Lilly Endowment IncMajor ShareholderSell245,000$62.68$15,356,600.00View SEC Filing  
6/20/2014Lilly Endowment IncMajor ShareholderSell230,000$61.55$14,156,500.00View SEC Filing  
6/16/2014Lilly Endowment IncMajor ShareholderSell200,000$58.73$11,746,000.00View SEC Filing  
6/5/2014Lilly Endowment IncMajor ShareholderSell190,000$59.53$11,310,700.00View SEC Filing  
5/21/2014Lilly Endowment Incmajor shareholderSell230,000$58.90$13,547,000.00134,690,804View SEC Filing  
5/12/2014Jackson TaiDirectorBuy17,157$59.19$1,015,522.8332,180View SEC Filing  
5/12/2014Lilly Endowment Incmajor shareholderSell210,000$59.33$12,459,300.00134,920,804View SEC Filing  
5/6/2014Lilly Endowment Incmajor shareholderSell190,000$58.79$11,170,100.00135,130,804View SEC Filing  
4/29/2014Lilly Endowment Incmajor shareholderSell200,000$59.43$11,886,000.00135,320,804View SEC Filing  
4/28/2014Lilly Endowment Incmajor shareholderSell150,000$58.64$8,796,000.00135,520,804View SEC Filing  
8/15/2013Enrique ConternoVPSell5,000$53.79$268,950.0057,177View SEC Filing  
7/29/2013Jacques TapieroSVPSell7,500$53.74$403,050.00View SEC Filing  
7/15/2013Enrique A ConternoVPSell5,000$51.43$257,150.00View SEC Filing  
6/17/2013Enrique A ConternoVPSell5,000$52.45$262,250.00View SEC Filing  
5/15/2013Enrique A ConternoVPSell5,000$56.15$280,750.00View SEC Filing  
5/10/2013Jeffrey N SimmonsSVPSell10,000$54.49$544,900.00View SEC Filing  
3/26/2013Susan MahonySVPSell5,000$56.00$280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Eli Lilly and (NYSE LLY) News Headlines

Source:
DateHeadline
Eli Lilly’s Human Pharmaceuticals Business in Q1 2018Eli Lilly’s Human Pharmaceuticals Business in Q1 2018
finance.yahoo.com - May 21 at 8:32 AM
Autoimmune Disease Treatment Market 2018 Outlook | Professional Survey Upcoming Treatments, Challenges, Scope, Analysis and Forecast Till 2023Autoimmune Disease Treatment Market 2018 Outlook | Professional Survey Upcoming Treatments, Challenges, Scope, Analysis and Forecast Till 2023
www.marketwatch.com - May 19 at 8:29 AM
Trump’s New Health and Human Services Secretary Is a Joyful RegulatorTrump’s New Health and Human Services Secretary Is a Joyful Regulator
www.nytimes.com - May 19 at 8:29 AM
$1.34 EPS Expected for Eli Lilly and Company (LLY) This Quarter$1.34 EPS Expected for Eli Lilly and Company (LLY) This Quarter
www.americanbankingnews.com - May 18 at 9:23 PM
Eli Lilly’s Revenue Trend in Q1 2018Eli Lilly’s Revenue Trend in Q1 2018
finance.yahoo.com - May 18 at 5:37 PM
Lawful But Never Substantial: Off-Label Use and Contributory Infringement in Hatch-Waxman LitigationLawful But Never Substantial: Off-Label Use and Contributory Infringement in Hatch-Waxman Litigation
finance.yahoo.com - May 18 at 9:04 AM
U.S. FDA approves Amgen migraine drug, price set at $6900/yrU.S. FDA approves Amgen migraine drug, price set at $6900/yr
finance.yahoo.com - May 18 at 9:04 AM
Brokers Set Expectations for Eli Lilly and Companys FY2022 Earnings (LLY)Brokers Set Expectations for Eli Lilly and Company's FY2022 Earnings (LLY)
www.americanbankingnews.com - May 18 at 8:43 AM
Possible Shift in Medicare Drug Organization May Give Pharma HeartburnPossible Shift in Medicare Drug Organization May Give Pharma Heartburn
finance.yahoo.com - May 17 at 5:58 PM
Eli Lilly & Co. (LLY) Says Data at ASCO Illustrate Patient-Driven Advances in Cancer CareEli Lilly & Co. (LLY) Says Data at ASCO Illustrate Patient-Driven Advances in Cancer Care
www.streetinsider.com - May 17 at 8:41 AM
3 Things In Biotech, May 16: Lillys No Headache, Aerie Eyes A Finish, Rexahn Swaps In Pancreatic Cancer3 Things In Biotech, May 16: Lilly's No Headache, Aerie Eye's A Finish, Rexahn Swaps In Pancreatic Cancer
seekingalpha.com - May 17 at 8:41 AM
Wired News – Eli Lilly’s Galcanezumab Met Primary Endpoint in Phase-3 Study for Prevention of Episodic Cluster HeadacheWired News – Eli Lilly’s Galcanezumab Met Primary Endpoint in Phase-3 Study for Prevention of Episodic Cluster Headache
finance.yahoo.com - May 17 at 8:41 AM
Eli Lillys Cluster Headache Candidate Succeeds in Phase IIIEli Lilly's Cluster Headache Candidate Succeeds in Phase III
finance.yahoo.com - May 16 at 5:21 PM
Eli Lilly's Cluster Headache Candidate Succeeds in Phase IIIEli Lilly's Cluster Headache Candidate Succeeds in Phase III
finance.yahoo.com - May 16 at 5:21 PM
Lilly Data at ASCO Illustrate Patient-Driven Advances in Cancer CareLilly Data at ASCO Illustrate Patient-Driven Advances in Cancer Care
finance.yahoo.com - May 16 at 5:21 PM
Eli Lilly and (LLY) Given a $82.00 Price Target at Credit Suisse GroupEli Lilly and (LLY) Given a $82.00 Price Target at Credit Suisse Group
www.americanbankingnews.com - May 16 at 3:21 PM
Eli Lillys Positive Phase 3 Results Along With Recent Acquisitions Makes It A Force To Be Reckoned WithEli Lilly's Positive Phase 3 Results Along With Recent Acquisitions Makes It A Force To Be Reckoned With
seekingalpha.com - May 16 at 8:42 AM
Global Lung Cancer Therapeutic Market Growth Opportunities: Eli Lilly and company, AstraZeneca PlcGlobal Lung Cancer Therapeutic Market Growth Opportunities: Eli Lilly and company, AstraZeneca Plc
www.marketwatch.com - May 16 at 8:42 AM
Eli Lilly (LLY) to Buy AurKa Pharma, Expand Cancer PipelineEli Lilly (LLY) to Buy AurKa Pharma, Expand Cancer Pipeline
finance.yahoo.com - May 15 at 5:35 PM
An Update on Teva’s Highly Anticipated Migraine DrugAn Update on Teva’s Highly Anticipated Migraine Drug
finance.yahoo.com - May 15 at 5:35 PM
Global Erectile Dysfunction Market Growth Opportunities: Endo Pharmaceuticals, Eli Lilly And CompanyGlobal Erectile Dysfunction Market Growth Opportunities: Endo Pharmaceuticals, Eli Lilly And Company
www.marketwatch.com - May 15 at 8:51 AM
Lilly (LLY) Says Galcanezumab Met Primary Endpoint in Phase 3 Study for Prevention of Episodic Cluster HeadacheLilly (LLY) Says Galcanezumab Met Primary Endpoint in Phase 3 Study for Prevention of Episodic Cluster Headache
www.streetinsider.com - May 15 at 8:51 AM
Lillys Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster HeadacheLilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache
finance.yahoo.com - May 15 at 8:51 AM
Eli Lillys galcanezumab successful in late-stage cluster headache studyEli Lilly's galcanezumab successful in late-stage cluster headache study
seekingalpha.com - May 15 at 8:51 AM
BRIEF-Eli Lilly Says Phase 3 Study For Patients With Chronic Cluster Headache Did Not Meet Its Primary EndpointBRIEF-Eli Lilly Says Phase 3 Study For Patients With Chronic Cluster Headache Did Not Meet Its Primary Endpoint
www.reuters.com - May 15 at 8:51 AM
Eli Lilly and Company (LLY) Major Shareholder Lilly Endowment Inc Sells 140,000 SharesEli Lilly and Company (LLY) Major Shareholder Lilly Endowment Inc Sells 140,000 Shares
www.americanbankingnews.com - May 14 at 4:19 PM
Celgene And Otezla Are CrackingCelgene And Otezla Are Cracking
seekingalpha.com - May 14 at 8:52 AM
Lilly To Buy AurKa PharmaLilly To Buy AurKa Pharma
www.nasdaq.com - May 14 at 8:52 AM
BRIEF-Eli Lilly To Acquire Aurka PharmaBRIEF-Eli Lilly To Acquire Aurka Pharma
www.reuters.com - May 14 at 8:52 AM
Global Diabetic Neuropathy Market Opportunities 2018: Eli Lilly and Company, Cephalon , Boehringer Ingelheim GmbH, Meda Pharma GmbHGlobal Diabetic Neuropathy Market Opportunities 2018: Eli Lilly and Company, Cephalon , Boehringer Ingelheim GmbH, Meda Pharma GmbH
www.marketwatch.com - May 14 at 8:52 AM
Lilly (LLY) to Acquire AurKa Pharma for $110M Upfront, Plus up to $465M in MilestonesLilly (LLY) to Acquire AurKa Pharma for $110M Upfront, Plus up to $465M in Milestones
www.streetinsider.com - May 14 at 8:52 AM
Eli Lilly to acquire AurKa Pharma for up to $545MEli Lilly to acquire AurKa Pharma for up to $545M
seekingalpha.com - May 14 at 8:52 AM
Eli Lilly to buy cancer drug developer AurKa PharmaEli Lilly to buy cancer drug developer AurKa Pharma
www.reuters.com - May 14 at 8:52 AM
Lilly to Acquire AurKa PharmaLilly to Acquire AurKa Pharma
finance.yahoo.com - May 14 at 8:52 AM
Eli Lilly Takes $7M Gamble On Global Health Working... In IndianaEli Lilly Takes $7M Gamble On Global Health Working... In Indiana
finance.yahoo.com - May 14 at 8:52 AM
Lilly to buy cancer drug developer AurKa PharmaLilly to buy cancer drug developer AurKa Pharma
finance.yahoo.com - May 14 at 8:52 AM
Eli Lilly and Company (LLY) Given Consensus Rating of "Hold" by AnalystsEli Lilly and Company (LLY) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - May 13 at 5:31 PM
Global Injection Pen Market Overview 2017-2026: Dickinson and Company, Astrazeneca plc, Eli Lilly and CompanyGlobal Injection Pen Market Overview 2017-2026: Dickinson and Company, Astrazeneca plc, Eli Lilly and Company
www.marketwatch.com - May 11 at 5:35 PM
[$$] Eli Lilly Buys Immunotherapy Cancer Treatment Company for $1.6 Billion[$$] Eli Lilly Buys Immunotherapy Cancer Treatment Company for $1.6 Billion
finance.yahoo.com - May 11 at 5:35 PM
Eli Lilly Makes A Bold Acquisition; How Lucrative Is It?Eli Lilly Makes A Bold Acquisition; How Lucrative Is It?
seekingalpha.com - May 11 at 8:57 AM
BRIEF-HBM Healthcare Investments: Eli Lilly Announces Tender Offer For HBM-Portfolio CompanyBRIEF-HBM Healthcare Investments: Eli Lilly Announces Tender Offer For HBM-Portfolio Company
www.reuters.com - May 11 at 8:57 AM
Eli Lilly Buys Immunotherapy Cancer Treatment Company for $1.6 BillionEli Lilly Buys Immunotherapy Cancer Treatment Company for $1.6 Billion
www.wsj.com - May 10 at 5:37 PM
Eli Lilly ands (LLY) "Hold" Rating Reiterated at BMO Capital MarketsEli Lilly and's (LLY) "Hold" Rating Reiterated at BMO Capital Markets
www.americanbankingnews.com - May 10 at 3:06 PM
Lilly to buy Armo Biosciences for $1.6 billion to bolster its cancer pipelineLilly to buy Armo Biosciences for $1.6 billion to bolster its cancer pipeline
www.cnbc.com - May 10 at 8:49 AM
Global Cancer Diagnostics Market Competitive landscape: Eli Lilly and Co, Abbott LaboratoriesGlobal Cancer Diagnostics Market Competitive landscape: Eli Lilly and Co, Abbott Laboratories
www.marketwatch.com - May 10 at 8:41 AM
Lilly to buy Armo Biosciences for $1.6 billion to bolster cancer pipelineLilly to buy Armo Biosciences for $1.6 billion to bolster cancer pipeline
www.reuters.com - May 10 at 8:41 AM
Warning to Eli Lillys Olumiant (baricitinib): Entrenched First-to-Market Rheumatoid Arthritis Products are Tough to UnseatWarning to Eli Lilly's Olumiant (baricitinib): Entrenched First-to-Market Rheumatoid Arthritis Products are Tough to Unseat
www.prnewswire.com - May 10 at 3:22 AM
Why Is It Wise To Pick Up Eli Lilly In 2018?Why Is It Wise To Pick Up Eli Lilly In 2018?
seekingalpha.com - May 9 at 5:18 PM
Global Diabetes Injection Pen Market Competitive landscape: Eli Lilly and Company, Novo Nordisk A/SGlobal Diabetes Injection Pen Market Competitive landscape: Eli Lilly and Company, Novo Nordisk A/S
www.marketwatch.com - May 9 at 8:37 AM
How Did Abraxane and Celgene’s Other Drugs Perform in 1Q18?How Did Abraxane and Celgene’s Other Drugs Perform in 1Q18?
finance.yahoo.com - May 9 at 8:37 AM

SEC Filings

Eli Lilly and (NYSE:LLY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Eli Lilly and (NYSE:LLY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Eli Lilly and (NYSE LLY) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.